Costs and effects of ultrasonography in the evaluation of palpable breast masses

International Journal of Technology Assessment in Health Care

Volumn 20, Issue 4, 2004, Pages 440-448

  Flobbe, Karin ^a   Kessels, Alfons G H ^a   Severens, Johan L ^a   Beets, Geerard L ^a   De Koning, Harry J ^b   Von Meyenfeldt, Maarten F ^a   Van Engelshoven, Jos M A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Breast neoplasms; Cost effectiveness; Diagnostic imaging; Ultrasonography

Indexed keywords

CLINICAL LABORATORIES; COST EFFECTIVENESS; DISEASE CONTROL; HEALTH CARE; MAMMOGRAPHY; PATIENT MONITORING; PUBLIC POLICY; ULTRASONIC EQUIPMENT;

BENIGN CANCER; COST-MINIMIZATION; FINE-NEEDLE ASPIRATION CYTOLOGY; ULTRASONOGRAPHY;

TUMORS;

ARTICLE; ASPIRATION CYTOLOGY; BREAST TUMOR; CLINICAL EXAMINATION; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; ECHOMAMMOGRAPHY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 8544229976     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462304001333     Document Type: Article

References (28)

1. American College of Radiology. Assessment categories: Illustrated breast imaging reporting and data system (Illustrated BI-RADS). Reston, VA: American College of Radiology; 1995.
2. Behandelingsrichtlijnen radiothérapie van het operabele mammacarcinoom na mamma-amputatie en okselkliertoilet in Nederland. Landelijk Platform voor Radiotherapie en Mammacarcinoom (LPRM) en NABON; 2000:1-13.
3. Farmacotherapeutisch Kompas 2000/2001: medisch farmaceutische voorlichting. Amstelveen: College voor Zorgverzekeringen; 2000.
4. Richtlijn diagnostiek en behandeling van primair mammacarcinoom. Maastricht: Integraal Kankercentrum Limburg; 1999: 1-66.
5. Agarwal T, Patel B, Rajan P, et al. Core biopsy versus FNAC for palpable breast cancers. Is image guidance necessary? Eur J Cancer. 2003;39:52-56.
6. Ciatto S, Cariaggi P, Bulgaresi P. The value of routine cytologic examination of breast cyst fluids. Acta Cytol. 1987;31:301-304.
7. de Koning HJ, van Ineveld BM, de Haes JC, et al. Advanced breast cancer and its prevention by screening. Br J Cancer. 1992;65:950-955.
8. de Koning HJ, van Ineveld BM, van Ootmarssen GJ, et al. De kosten en effecten van bevolkingsondenoek naar borstkanker. Eindrapport Kosten-effectiviteits Analyse. Rotterdam: Instituut Maatschappelijke Gezondheidszorg, Erasmus Universiteit Rotterdam; 1990:1-194.
9. Dey P, Bundred N, Gibbs A, et al. Costs and benefits of a one stop clinic compared with a dedicated breast clinic: Randomised controlled trial. BMJ. 2002;324:507.
10. Eltahir A, Jibril JA, Squair J, et al. The accuracy of "one-stop" diagnosis for 1,110 patients presenting to a symptomatic breast clinic. J R Coll Surg Edinb. 1999;44:226-230.
11. Flobbe K, Bosch AM, Kessels AG, et al. The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. Arch Intern Med. 2003;163:1194-1199.
12. Freedman GM, Fowble BL. Local recurrence after mastectomy or breast-conserving surgery and radiation. Oncology (Huntingt). 2000;14:1561-1581; discussion 1581-1582, 1582-1584.
13. Gui GP, Allum WH, Perry NM, et al. One-stop diagnosis for symptomatic breast disease. Ann R Coll Surg Engl. 1995;77:24-27.
14. Hardy JR, Powles TJ, Judson I, et al. How many tests are required in the diagnosis of palpable breast abnormalities? Clin Oncol (R Coll Radiol). 1990;2:148-152.
15. Hermansen C, Skovgaard Poulsen H, Jensen J, et al. Diagnostic reliability of combined physical examination, mammography, and fine-needle puncture ("triple-test") in breast tumors. A prospective study. Cancer. 1987;60:1866-1871.
16. Hurley SF, Huggins RM, Snyder RD, Bishop JF. The cost of breast cancer recurrences. Br J Cancer. 1992;65:449-455.
17. Lister D, Evans AJ, Burrell HC, et al. The accuracy of breast ultrasound in the evaluation of clinically benign, symptomatic breast lumps. Clin Radiol. 1998;53:490-492.
18. Mendelson EB, Berg WA, Merritt CR. Toward a standardized breast ultrasound lexicon, BI-RADS: Ultrasound. Semin Roentgenol. 2001;36:217-225.
19. van Oord JC, van der Vliet AM, Thyn CJ, Mak B, Hoogeboom GJ. The value of ultrasound mammography in palpable breast masses. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1991;155:63-66.
20. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en richtlijnen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor Zorgverzekeringen; 2000.
21. Perre CI, de Hooge P, Hustinx PA, Muller JW. [Ultrasonographic study of the palpable breast tumor is very useful]. Ned Tijdschr Geneeskd. 1993;137:2374-2377.
22. Richards MA, Braysher S, Gregory WM, Rubens RD. Advanced breast cancer: Use of resources and cost implications. Br J Cancer. 1993;67:856-860.
23. Sakorafas GH, Tsiotou AG. Selection criteria for breast conservation in breast cancer. Eur J Surg. 2000;166:835-846.
24. Slotman BJ, Levendag PC, Botke G, Leer JWH. Producttypering in de radiotherapie. Medisch Contact. 2000;55:1198-1201.
25. van Tienhoven G, Voogd AC, Peterse JL, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer. 1999;35:32-38.
26. Vetto J, Pommier R, Schmidt W, et al. Use of the "triple test" for palpable breast lesions yields high diagnostic accuracy and cost savings. Am J Surg. 1995;169:519-522.
27. Will BP, Berthelot JM, Le Petit C, et al. Estimates of the life-time costs of breast cancer treatment in Canada. Eur J Cancer. 2000;36:724-735.
28. Yang WTY, Mok CO, King W, Tang A, Metreweli C. Role of high frequency ultrasonography in the evaluation of palpable breast masses in Chinese women. J Ultrasound Med. 1996;15:637-644.